OBJECTIVES: The aim of this longitudinal study was to test the hypothesis that CSF biomarkers in AD patients also may be forward-looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time. METHODS: Here, we assessed the association of CSF Abeta42, T-tau and P-tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3-year prospective longitudinal treatment study. RESULTS: A more rapid progress in MMSE score reduction was seen in AD patients with T-tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's disease patients with lower T-tau levels (p = 0.008). We also found that individuals with T-tau > 800 ng/L performed worse in total scores and especially in memory and orientation when assessed with MMSE and ADAS cog than patients with T-tau <800 ng/L. Similar results were obtained for P-tau. No associations were seen between Abeta42 and cognitive scores or disease progression. DISCUSSION: These findings support the hypothesis that increased levels of T-tau reflect the intensity of the disease and are associated with a more rapid disease progress.
OBJECTIVES: The aim of this longitudinal study was to test the hypothesis that CSF biomarkers in ADpatients also may be forward-looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time. METHODS: Here, we assessed the association of CSF Abeta42, T-tau and P-tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3-year prospective longitudinal treatment study. RESULTS: A more rapid progress in MMSE score reduction was seen in ADpatients with T-tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's diseasepatients with lower T-tau levels (p = 0.008). We also found that individuals with T-tau > 800 ng/L performed worse in total scores and especially in memory and orientation when assessed with MMSE and ADAS cog than patients with T-tau <800 ng/L. Similar results were obtained for P-tau. No associations were seen between Abeta42 and cognitive scores or disease progression. DISCUSSION: These findings support the hypothesis that increased levels of T-tau reflect the intensity of the disease and are associated with a more rapid disease progress.
Authors: Katherine A Gifford; Dandan Liu; Jacquelyn E Neal; Lealani Mae Y Acosta; Susan P Bell; Margaret E Wiggins; Kristi M Wisniewski; Mary Godfrey; Laura A Logan; Timothy J Hohman; Kimberly R Pechman; David J Libon; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson Journal: Assessment Date: 2018-05-29
Authors: Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel Journal: Alzheimers Dement Date: 2014-05-03 Impact factor: 21.566
Authors: Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski Journal: Exp Gerontol Date: 2009-10-22 Impact factor: 4.032